Intralesional Interferon Gamma Treatment for Keloids and Hypertrophic Scars
- 1 October 1990
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 116 (10) , 1159-1162
- https://doi.org/10.1001/archotol.1990.01870100053011
Abstract
• Keloids and hypertrophic scars are characterized by excessive collagen formation. Interferon gamma is a lymphokine that can down-regulate collagen synthesis in vitro and in vivo and, therefore, has potential therapeutic benefit in the management of abnormal scars. Intralesional scar injections of interferon gamma were performed to determine the tolerance toxicity and to obtain preliminary evidence for the efficacy of this treatment in the management of hypertropic and keloid lesions. All scars decreased in linear dimensions and flattened out. Five of 10 scars studied decreased at least 50% in linear dimensions. Interferon gamma can safely be administered intralesionally once per week up to a dosage of 0.05 mg for 10 weeks with no serious toxic effects. The commonest reported side effect was a mild headache. (Arch Otolaryngol Head Neck Surg. 1990;116:1159-1162)This publication has 11 references indexed in Scilit:
- Recombinant interferon-γ in the treatment of systemic sclerosisThe American Journal of Medicine, 1989
- Role of ionizing irradiation for 393 keloidsInternational Journal of Radiation Oncology*Biology*Physics, 1988
- Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.Proceedings of the National Academy of Sciences, 1987
- Gamma-interferon inhibits collagen synthesis in vivo in the mouse.Journal of Clinical Investigation, 1987
- Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes.Journal of Biological Chemistry, 1986
- Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.Proceedings of the National Academy of Sciences, 1986
- A phase I trial of recombinant gamma interferon in patients with cancerCancer Immunology, Immunotherapy, 1985
- Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation.The Journal of Experimental Medicine, 1985
- PHARMACOKINETICS, SINGLE-DOSE TOLERANCE, AND BIOLOGICAL-ACTIVITY OF RECOMBINANT GAMMA-INTERFERON IN CANCER-PATIENTS1985
- Mononuclear Cell-Conditioned Medium Containing Mononuclear Cell Factor (MCF), Homologous With Interleukin 1, Stimulates Collagen and Fibronectin Synthesis by Adherent Rheumatoid Synovial Cells: Effects of Prostaglandin E2 and IndomethacinCollagen and Related Research, 1985